Purple Biotech Ltd. (PPBT)
Automate Your Wheel Strategy on PPBT
With Tiblio's Option Bot, you can configure your own wheel strategy including PPBT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PPBT
- Rev/Share 0.0
- Book/Share 0.0
- PB 0.0
- Debt/Equity 0.0
- CurrentRatio 0.0
- ROIC 0.0
- MktCap 6911802.0
- FreeCF/Share -0.027
- PFCF -0.7442
- PE -1.2911
- Debt/Assets 0.0
- DivYield 0
- ROE -0.1519
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
---|---|---|---|---|---|---|---|
No ratings available. |
News
Purple Biotech Reports First Quarter 2025 Financial Results
Published: May 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
Final CM24 Phase 2 data presented at AACR Annual Meeting 2025, strengthening patient selection strategy for CM24 Phase 2b study planned to be initiated in Second Half of 2025
Read More
Purple Biotech Appoints Shai Lankry as Chief Financial Officer
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
U.S.-based Lankry brings over 20 years of financial leadership in biotech and healthcare with a proven track record of driving strategic growth, operational excellence, and capital market execution, including leading a U.S. IPO and M&A transaction
Read More
Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the standard-of-care head and neck cancer drugs pembrolizumab (Keytruda) or cetuximab (Erbitux)
Read More
About Purple Biotech Ltd. (PPBT)
- IPO Date 2015-11-20
- Website https://purple-biotech.com
- Industry Biotechnology
- CEO Dr. Michael Schickler Ph.D.
- Employees 9